This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Real validated LOX Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-LOX WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
| Expected band | ~46.9 kDa | |
| Observed band | ~47 kDa | |
| Gel | 10–12% | |
| Negative control | siRNA / KO lysate |
| PTM | Glycosylated + Cleaved | |
| Caveat | Propeptide cleavage | |
| Regulation | Hypoxia up | |
| Isoform | 1 isoform(s) |
Literature-validated Western blot parameters for LOX — gel percentage, transfer, blocking, antibody incubation and detection, extracted from published methods.
| Sample / lysate | rat liver , Lane 2: rat lung , Lane 3: mouse liver . After Electrophoresis, proteins were transferred to a Nitrocellulose membrane at 150mA for 50-90 minutes. Blocked the membrane with 5% Non-fat Milk/ TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti-LOX antigen affinity purified polyclonal antibody (Catalog # PB9718) at 0.5 μg/mL overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:5000 for 1.5 hour at RT. The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit (Catalog # EK1002) with Tanon 5200 system. A specific band was detected for LOX at approximately 47 kDa. The expected band size for LOX is at 47 kDa |
| Gel % | 10–12% |
| Load | 30 ug |
| Transfer | nitrocellulose membrane, 150 mA, 50–90 min |
| Membrane | nitrocellulose |
| Blocking | 5% non-fat milk / TBS, 1.5 h RT |
| Primary antibody | 0.5 µg/mL |
| Primary incubation | overnight at 4 °C |
| Secondary antibody | goat anti-rabbit IgG-HRP, 1:5000 |
| Wash | TBS-0.1% Tween, 3 × 5 min |
| Detection | ECL |
| Exposure / imaging | Tanon 5200 |
| Observed band | 47 kDa |
LOX has a 46.9 kDa predicted mass and runs at the empirically observed ~47 kDa as the secreted proenzyme, with propeptide N-glycosylation accounting for the slight upward shift.
| single band near 47 kDa | matches the secreted full-length LOX proenzyme after signal peptide cleavage, close to the 46.9 kDa predicted mass |
| band running slightly above the 46.9 kDa predicted mass | N-linked glycosylation at three sites (Asn81, Asn97, Asn144) within the retained propeptide adds modest mass to the secreted proenzyme |
| little or no band in whole-cell lysate | LOX is a secreted, extracellular protein, so most of it leaves the cell rather than staying in the cytoplasmic fraction |
| smaller ~30 kDa and ~18 kDa bands appearing alongside or instead of the ~47 kDa band | extracellular proteolytic cleavage between the propeptide (22-168) and the mature chain (169-417) separates a catalytic fragment from a propeptide fragment |
| slightly diffuse or fuzzy edge on the ~47 kDa band | partial or heterogeneous occupancy of the three N-glycosylation sites in the propeptide produces minor size heterogeneity |
| Predicted mass (UniProt, 417 aa) | sets the 46.9 kDa reference point for the intact secreted proenzyme |
| Signal peptide cleavage (residues 1-21) | removed upon secretion, so the extracellular/lysate-detectable form runs slightly lower than the unprocessed intracellular precursor |
| Propeptide retention vs cleavage (residues 22-168) | an intact propeptide keeps the secreted band near the full ~47 kDa size, while its extracellular removal produces a smaller mature catalytic fragment |
| N-linked glycosylation at Asn81, Asn97, Asn144 | adds modest mass and can broaden the band slightly above the unmodified predicted size |
| Secreted/extracellular localization | protein is depleted from standard whole-cell lysate and better recovered from conditioned media, ECM-enriched, or tissue fractions |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | LOX is secreted into the extracellular space/matrix rather than retained inside the cell | probe conditioned media, ECM-enriched or decellularized matrix fractions, or whole tissue lysates instead of standard cytoplasmic lysate |
| Band higher than expected | N-glycosylation at the three propeptide sites adds mass to the secreted proenzyme | treat the sample with PNGase F and confirm the band shifts toward the 46.9 kDa predicted mass |
| Fragments below expected size | extracellular proteolytic maturation cleaves the propeptide (22-168) from the mature chain (169-417), releasing smaller species | add protease inhibitors during extraction and interpret smaller fragments as physiological maturation products rather than degradation |
| Broad smear instead of sharp band | heterogeneous occupancy of the three N-glycosylation sites in the propeptide | run deglycosylated (PNGase F-treated) and untreated samples side by side to sharpen and confirm the band |
| Weak or no signal | standard lysis buffers are not designed to capture secreted, matrix-associated LOX | concentrate conditioned media or use matrix-extraction methods and load higher total protein |
| Multiple bands | coexistence of the full-length ~47 kDa proenzyme with cleaved mature and propeptide fragments in tissue samples | compare across tissues and, if available, use antibodies targeting the propeptide versus the mature domain to assign each band |
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
| Tissue | Cell type | Level | Evidence | Source |
|---|
| Tissue | Cell type | Level | Evidence | Source |
|---|
Deeper troubleshooting and optimisation questions for LOX, answered from its protein features.
BosterBio's LOX antibodies are among the best-performing WB antibodies on the market — well cited, thoroughly validated, and orthogonally cross-validated against negative tissues and complementary methods.
Our top-performing anti-LOX antibodies are extensively cited and rigorously validated, with specificity confirmed via orthogonal methods including negative-tissue controls and complementary detection techniques, ensuring reliable, reproducible Western blot results for LOX detection across applications.
Which to pick: Only one Boster anti-LOX antibody is currently catalogued, PB9718, which includes an actual Western blot validation image on a 5-20% SDS-PAGE gel, making it the clear default choice for LOX WB experiments.